Belatacept Injection

DRUG2 trials

Sponsors

Nantes University Hospital, University of Chicago

Conditions

End Stage Kidney Disease (ESRD)Heart Transplant FailureKidney Transplantation

Phase 1

Novel Desensitization Kidney Transplantation

CompletedNCT05345717

University of ChicagoEnd Stage Kidney Disease (ESRD), Kidney Transplantation

Start: 2022-05-01End: 2025-09-12Updated: 2025-12-09

Phase 2

Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)

RecruitingNCT04180085

Nantes University HospitalHeart Transplant Failure

Start: 2020-02-06End: 2028-01-01Target: 25Updated: 2026-01-15